In a groundbreaking step forward for cancer treatment, Zymeworks has announced positive results from its Phase 3 HERIZON-GEA-01 clinical trial, assessing the effectiveness of its drug Ziihera in treating HER2-positive gastroesophageal adenocarcinoma. The announcement on Monday caused Zymeworks’ stock to soar by 57%, with Jazz Pharmaceuticals and BeOne Medicines joining in on the success with a 21% and 3.9% jump in their stock values, respectively.
Why This Matters in Cancer Treatment
Gastroesophageal adenocarcinoma is a challenging and aggressive form of cancer, especially in patients diagnosed with HER2-positive tumors. Ziihera, when paired with chemotherapy or in a three-drug combination including Tevimbra, has shown a statistically significant improvement in both progression-free survival (PFS) and overall survival (OS) compared to the current standard treatment of trastuzumab with chemotherapy.
Key Results of the HERIZON-GEA-01 Trial
- Combination of Ziihera plus chemotherapy: Demonstrated clinically significant and statistically improved PFS compared to the trastuzumab and chemotherapy combination.
- Three-drug combination (Ziihera, Tevimbra, and chemotherapy): Delivered superior results in both PFS and OS versus the control group.
With its outstanding safety profile, Ziihera remains consistent with known safety characteristics of existing agents, with no new adverse signals observed in the clinical trial.
Future Implications and Next Steps
Jazz Pharmaceuticals acquired the development and commercialization rights for Ziihera from Zymeworks in 2022. Following the success of the Phase 3 trial, Jazz is planning to submit a supplemental Biologics License Application (sBLA) within the first half of 2026. This move ensures that Ziihera will be reviewed for first-line treatment approval in HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma patients.
Ziihera already has approval for the treatment of second-line biliary tract cancer in the United States, Europe, and China. As of now, BeOne Medicines retains commercialization rights for Ziihera across the Asia-Pacific region.
Professional Insights
Rob Iannone, Chief Medical Officer at Jazz Pharmaceuticals, emphasized the life-changing potential of Ziihera, stating its trial results could redefine treatment practices. According to Iannone, these advances bring new hope to patients who currently have limited treatment options.
Explore Patient Skincare Options During Chemotherapy
Cancer treatments and the associated chemotherapy can significantly impact skin health, causing dryness and sensitivity. For patients undergoing chemotherapy, products like Cetaphil Restoraderm Skin Restoring Moisturizer provide hydration and relief from dryness. This dermatologist-recommended product is gentle on sensitive skin, making it ideal for cancer patients in need of skincare relief.
Looking Ahead: A Step Towards Improved Oncology Guidelines
As Ziihera continues its journey toward integration into the National Comprehensive Cancer Network (NCCN) Guidelines, the oncology community eagerly awaits the complete data presentation at a renowned medical conference in early 2026. These developments highlight the importance of continuing innovation in cancer research, providing better outcomes for patients worldwide.